As of 2026-05-20, the EV/EBITDA ratio of Regenxbio Inc (RGNX) is -4.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RGNX's latest enterprise value is 691.40 mil USD. RGNX's TTM EBITDA according to its financial statements is -145.58 mil USD. Dividing these 2 quantities gives us the above RGNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.5x - 17.2x | 15.4x |
| Forward P/E multiples | 17.8x - 24.6x | 19.8x |
| Fair Price | (28.85) - (27.97) | (28.55) |
| Upside | -609.8% - -594.1% | -604.5% |
| Date | EV/EBITDA |
| 2026-05-14 | -5.06 |
| 2026-05-13 | -7.61 |
| 2026-05-12 | -7.74 |
| 2026-05-11 | -7.64 |
| 2026-05-08 | -7.95 |
| 2026-05-07 | -7.86 |
| 2026-05-06 | -7.73 |
| 2026-05-05 | -7.08 |
| 2026-05-04 | -7.19 |
| 2026-05-01 | -7.01 |
| 2026-04-30 | -6.91 |
| 2026-04-29 | -6.54 |
| 2026-04-28 | -6.73 |
| 2026-04-27 | -6.68 |
| 2026-04-24 | -6.78 |
| 2026-04-23 | -6.93 |
| 2026-04-22 | -7.16 |
| 2026-04-21 | -7.01 |
| 2026-04-20 | -7.24 |
| 2026-04-17 | -7.25 |
| 2026-04-16 | -7.06 |
| 2026-04-15 | -7.17 |
| 2026-04-14 | -7.13 |
| 2026-04-13 | -6.96 |
| 2026-04-10 | -6.80 |
| 2026-04-09 | -6.91 |
| 2026-04-08 | -6.72 |
| 2026-04-07 | -6.80 |
| 2026-04-06 | -6.80 |
| 2026-04-02 | -6.63 |
| 2026-04-01 | -6.69 |
| 2026-03-31 | -6.53 |
| 2026-03-30 | -6.13 |
| 2026-03-27 | -6.12 |
| 2026-03-26 | -6.45 |
| 2026-03-25 | -6.58 |
| 2026-03-24 | -6.16 |
| 2026-03-23 | -6.50 |
| 2026-03-20 | -6.34 |
| 2026-03-19 | -6.51 |
| 2026-03-18 | -6.46 |
| 2026-03-17 | -6.70 |
| 2026-03-16 | -6.80 |
| 2026-03-13 | -6.65 |
| 2026-03-12 | -6.99 |
| 2026-03-11 | -7.18 |
| 2026-03-10 | -7.52 |
| 2026-03-09 | -7.84 |
| 2026-03-06 | -6.70 |
| 2026-03-05 | -6.75 |